ImmunoGen, Inc., a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Jazz Pharmaceuticals plc; and Debiopharm International SA. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:IMGN
CUSIP45253H10
Phone781-895-0600
Debt
Debt-to-Equity Ratio0.02
Current Ratio5.76
Quick Ratio5.73
Price-To-Earnings
Trailing P/E Ratio-12.15
Forward P/E Ratio-7.54
P/E GrowthN/A
Sales & Book Value
Annual Sales$115.45 million
Price / Sales11.68
Cash FlowN/A
Price / CashN/A
Book Value($0.14) per share
Price / Book-64.64
Profitability
EPS (Most Recent Fiscal Year)($0.75)
Net Income$-96,010,000.00
Net Margins-194.78%
Return on EquityN/A
Return on Assets-43.36%
Miscellaneous
Employees293
Outstanding Shares149,020,000
Market Cap$1.33 billion
ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions
What is ImmunoGen's stock symbol?
ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."
How were ImmunoGen's earnings last quarter?
ImmunoGen, Inc. (NASDAQ:IMGN) released its quarterly earnings results on Friday, July, 27th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.02. The biotechnology company had revenue of $9.29 million for the quarter, compared to analyst estimates of $14.12 million. The company's quarterly revenue was down 76.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.10) earnings per share. View ImmunoGen's Earnings History.
When is ImmunoGen's next earnings date?
What price target have analysts set for IMGN?
7 Wall Street analysts have issued 1-year price targets for ImmunoGen's stock. Their forecasts range from $5.00 to $20.00. On average, they anticipate ImmunoGen's stock price to reach $13.60 in the next year. This suggests a possible upside of 50.3% from the stock's current price. View Analyst Price Targets for ImmunoGen.
What is the consensus analysts' recommendation for ImmunoGen?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ImmunoGen.
What are Wall Street analysts saying about ImmunoGen stock?
Here are some recent quotes from research analysts about ImmunoGen stock:
- 1. According to Zacks Investment Research, "ImmunoGen reported dismal second-quarter results, wherein the company missed estimates on both counts. However, the company has made significant progress with regard to its lead ovarian cancer candidate, mirvetuximab soravtansine. Successful development and subsequent approval of the candidate will be a huge boost to the company as the ovarian cancer market has immense potential. The company has collaborations with big healthcare companies which not only validate its technology but also provides it with funds in the form of milestone and royalty payments. However, ImmunoGen is heavily dependent on its lead candidate, mirvetuximab soravtansine. Hence, any kind of development or a regulatory setback could hamper the stock. The ovarian cancer space being competitive is also a matter of concern for the company. The company’s shares have outperformed the industry so far this year." (8/2/2018)
- 2. HC Wainwright analysts commented, "Our 12-month, $18 price target on shares of ImmunoGen is based on a 13-year DCF-driven, sum-of-the-parts analysis. Our DCF analysis is based on: beta of 1.9, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 12.5%, and tax rate of 12% beginning in FY 2028. Note, our $18 price target is leveraged on the outcome of the mirvetuximab soravtansine’s Phase 3 FORWARD I study, which represents approximately 89% of our target (risk-adjusted NPV of $16 per share). Key risks to our valuation include: emergence of ADC-related safety concerns, clinical, regulatory, and financials risks. ImmunoGen, Inc." (7/30/2018)
- 3. Cantor Fitzgerald analysts commented, "FORWARD Progress. The nearest term commercial opportunity for IMGN is the FORWARD I trial, which is exploring mirvetuximab soravtansine (mirva") as a single agent in 3rd line ovarian cancer in women who express high levels of the FRa receptor. This trial could read out in 2019 pending completion of enrollment in 2018." (11/3/2017)
- 4. Cowen Inc analysts commented, "IMGN announced a collaboration agreement with Jazz for the development and." (8/29/2017)
Who are some of ImmunoGen's key competitors?
Some companies that are related to ImmunoGen include Ligand Pharmaceuticals (LGND), FibroGen (FGEN), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC- (GWPH), Madrigal Pharmaceuticals (MDGL), Endo International (ENDP), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Array Biopharma (ARRY) and Opko Health (OPK).
Who are ImmunoGen's key executives?
ImmunoGen's management team includes the folowing people:
- Mr. Mark J. Enyedy, Pres, CEO & Director (Age 54)
- Mr. David B. Johnston, Exec. VP & CFO (Age 63)
- Dr. Richard J. Gregory, Exec. VP & Chief Scientific Officer (Age 60)
- Mr. Craig Barrows, Exec. VP, Gen. Counsel & Sec. (Age 63)
- Dr. Anna Berkenblit, VP & Chief Medical Officer (Age 48)
Has ImmunoGen been receiving favorable news coverage?
News headlines about IMGN stock have trended somewhat positive on Monday, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ImmunoGen earned a daily sentiment score of 0.05 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 46.86 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for ImmunoGen.
Who are ImmunoGen's major shareholders?
ImmunoGen's stock is owned by many different of institutional and retail investors. Top institutional investors include Redmile Group LLC (8.26%), BlackRock Inc. (7.00%), FMR LLC (5.84%), Renaissance Technologies LLC (4.38%), Morgan Stanley (2.37%) and Orbimed Advisors LLC (1.95%). Company insiders that own ImmunoGen stock include Craig Barrows, Daniel M Junius, David Brannon Johnston, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Institutional Ownership Trends for ImmunoGen.
Which institutional investors are selling ImmunoGen stock?
IMGN stock was sold by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., Morgan Stanley, GSA Capital Partners LLP, Bank of New York Mellon Corp, Alps Advisors Inc., Alps Advisors Inc., California Public Employees Retirement System and Baxter Bros Inc.. Company insiders that have sold ImmunoGen company stock in the last year include Craig Barrows, Daniel M Junius, David Brannon Johnston, Mark J Enyedy and Richard J Gregory. View Insider Buying and Selling for ImmunoGen.
Which institutional investors are buying ImmunoGen stock?
IMGN stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, FMR LLC, BlackRock Inc., Point72 Asset Management L.P., Voya Investment Management LLC, Renaissance Technologies LLC, Orbimed Advisors LLC and Jennison Associates LLC. Company insiders that have bought ImmunoGen stock in the last two years include Craig Barrows, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Insider Buying and Selling for ImmunoGen.
How do I buy shares of ImmunoGen?
Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ImmunoGen's stock price today?
One share of IMGN stock can currently be purchased for approximately $9.05.
How big of a company is ImmunoGen?
ImmunoGen has a market capitalization of $1.33 billion and generates $115.45 million in revenue each year. The biotechnology company earns $-96,010,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. ImmunoGen employs 293 workers across the globe.
How can I contact ImmunoGen?
ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]
MarketBeat Community Rating for ImmunoGen (NASDAQ IMGN)
MarketBeat's community ratings are surveys of what our community members think about ImmunoGen and other stocks. Vote "Outperform" if you believe IMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
